Expect more mergers and acquisitions among the listed gold miners, says broker Liberum, with attention now likely turn towards mid-sized producers such as Caledonia and Shanta Gold.
A rash of takeovers has broken out among the giants such as Newmont/Newcrest, Yamana/ Agnico but the spotlight is now likely to move down the chain reckons the broker.
Iofina PLC (AIM:IOF, OTC:IOFNF) has increased production slightly in the three months to March even with cooler weather and weather-related disruption.
Output totalled 107.1 metric tonnes (MT) of crystalline iodine from its IOsorb iodine plants in Oklahoma, up 3.3 MT from the same period in 2022.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said the US Food and Drug Administration (FDA) has called a pre-investigational new drug (IND) meeting for 16 May 2023 to discuss a phase II/II adaptive trial study protocol for lead asset P140.
The regulator will consider a new use for the treatment: namely, chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disease with high medical need.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been issued a trademark registration for RECCE® from the Israeli Patent Office, Trademarks Department, in an effort to tap into the burgeoning Israeli pharmaceutical and biotech market.
This newly registered trademark further strengthens the company’s intellectual property portfolio with those already registered in the biggest pharmaceutical markets in the world such as Australia, USA, Europe, Japan, China and most recently in Hong Kong.